Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Influenza virus N-linked glycosylation and innate immunity.

York IA, Stevens J, Alymova IV.

Biosci Rep. 2019 Jan 8;39(1). pii: BSR20171505. doi: 10.1042/BSR20171505. Print 2019 Jan 31. Review.

2.

Virulent PB1-F2 residues: effects on fitness of H1N1 influenza A virus in mice and changes during evolution of human influenza A viruses.

Alymova IV, McCullers JA, Kamal RP, Vogel P, Green AM, Gansebom S, York IA.

Sci Rep. 2018 May 10;8(1):7474. doi: 10.1038/s41598-018-25707-y.

3.

Evolution and Virulence of Influenza A Virus Protein PB1-F2.

Kamal RP, Alymova IV, York IA.

Int J Mol Sci. 2017 Dec 29;19(1). pii: E96. doi: 10.3390/ijms19010096. Review.

4.

Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence.

Alymova IV, York IA, Air GM, Cipollo JF, Gulati S, Baranovich T, Kumar A, Zeng H, Gansebom S, McCullers JA.

Sci Rep. 2016 Oct 31;6:36216. doi: 10.1038/srep36216.

5.

Non-avian animal reservoirs present a source of influenza A PB1-F2 proteins with novel virulence-enhancing markers.

Alymova IV, York IA, McCullers JA.

PLoS One. 2014 Nov 4;9(11):e111603. doi: 10.1371/journal.pone.0111603. eCollection 2014.

6.

A novel cytotoxic sequence contributes to influenza A viral protein PB1-F2 pathogenicity and predisposition to secondary bacterial infection.

Alymova IV, Samarasinghe A, Vogel P, Green AM, Weinlich R, McCullers JA.

J Virol. 2014 Jan;88(1):503-15. doi: 10.1128/JVI.01373-13. Epub 2013 Oct 30.

7.

Immunopathogenic and antibacterial effects of H3N2 influenza A virus PB1-F2 map to amino acid residues 62, 75, 79, and 82.

Alymova IV, Green AM, van de Velde N, McAuley JL, Boyd KL, Ghoneim HE, McCullers JA.

J Virol. 2011 Dec;85(23):12324-33. doi: 10.1128/JVI.05872-11. Epub 2011 Sep 21.

8.

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Alymova IV, Portner A, Mishin VP, McCullers JA, Freiden P, Taylor GL.

Glycobiology. 2012 Feb;22(2):174-80. doi: 10.1093/glycob/cwr112. Epub 2011 Aug 16.

9.

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.

Mishin VP, Watanabe M, Taylor G, Devincenzo J, Bose M, Portner A, Alymova IV.

J Virol. 2010 Mar;84(6):3094-100. doi: 10.1128/JVI.02331-09. Epub 2010 Jan 6.

10.

Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice - further evaluation.

Alymova IV, Watanabe M, Boyd KL, Chand P, Babu YS, Portner A.

Antivir Ther. 2009;14(7):891-8. doi: 10.3851/IMP1420.

11.

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS, Taylor G, Xiong X, Yan X, Portner A, Alymova IV.

Antimicrob Agents Chemother. 2009 Sep;53(9):3942-51. doi: 10.1128/AAC.00220-09. Epub 2009 Jun 29.

12.

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Alymova IV, Taylor G, Mishin VP, Watanabe M, Murti KG, Boyd K, Chand P, Babu YS, Portner A.

J Virol. 2008 Sep;82(17):8400-10. doi: 10.1128/JVI.00474-08. Epub 2008 Jun 25.

13.

Neuraminidase inhibitors as antiviral agents.

Alymova IV, Taylor G, Portner A.

Curr Drug Targets Infect Disord. 2005 Dec;5(4):401-9. Review.

PMID:
16535861
14.

The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae.

Alymova IV, Portner A, Takimoto T, Boyd KL, Babu YS, McCullers JA.

Antimicrob Agents Chemother. 2005 Jan;49(1):398-405.

15.

Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Alymova IV, Taylor G, Takimoto T, Lin TH, Chand P, Babu YS, Li C, Xiong X, Portner A.

Antimicrob Agents Chemother. 2004 May;48(5):1495-502.

16.

Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs.

Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG.

Dev Biol Stand. 1999;98:39-51; discussion 73-4.

PMID:
10494958
17.

Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents.

Burstein ME, Serbin AV, Khakhulina TV, Alymova IV, Stotskaya LL, Bogdan OP, Manukchina EE, Jdanov VV, Sharova NK, Bukrinskaya AG.

Antiviral Res. 1999 Apr;41(3):135-44.

PMID:
10320046
18.

Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG.

J Virol. 1998 May;72(5):4472-7.

Supplemental Content

Loading ...
Support Center